Invesco’s ProQR Therapeutics PRQR Stock Holding History

Invesco’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-44,592	Closed	-$72.2K	–	3916
2026 Q1	$72.2K	Buy	44,592 +19,245	+76%	+$31.5K	﹤0.01%	3660
2025 Q4	$51.2K	Buy	+25,347	New	+$59.2K	﹤0.01%	3703
2025 Q2	–	Sell	-18,084	Closed	-$24.1K	–	3844
2025 Q1	$24.1K	Buy	18,084 +6,197	+52%	+$13.2K	﹤0.01%	3738
2024 Q4	$31.5K	Buy	+11,887	New	+$37.7K	﹤0.01%	3724
2023 Q4	–	Sell	-20,822	Closed	-$27.1K	–	3883
2023 Q3	$27.1K	Buy	20,822 +1,700	+9%	+$2.67K	﹤0.01%	3843
2023 Q2	$31K	Buy	+19,122	New	+$37.3K	﹤0.01%	3846

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Invesco's PRQR Position: Q2 2026 in Review

Invesco sold out of ProQR Therapeutics (PRQR) in Q2 2026, closing a stake of 44,592 shares — an estimated $72.2K sold.

Invesco first reported a position in PRQR in Q2 2023 and held it in 6 quarters. The position peaked at $72.2K in Q1 2026. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

Invesco reported no remaining ProQR Therapeutics position as of Q2 2026 after selling out during the quarter.
Invesco sold 44,592 ProQR Therapeutics shares in Q2 2026, an estimated $72.2K.
Invesco first reported a position in ProQR Therapeutics in Q2 2023 and held it in 6 quarters.
Invesco's ProQR Therapeutics position peaked at $72.2K in Q1 2026.
70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.